Analysts Set Bruker Co. (NASDAQ:BRKR) PT at $79.36

Shares of Bruker Co. (NASDAQ:BRKR) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $79.36.

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company lowered their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Barclays reduced their price target on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. TD Cowen lowered their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. Finally, Citigroup dropped their price objective on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th.

Bruker Stock Down 4.6 %

Bruker stock opened at $57.73 on Friday. The firm has a market capitalization of $8.74 billion, a price-to-earnings ratio of 27.75, a P/E/G ratio of 2.83 and a beta of 1.20. The firm has a 50 day simple moving average of $63.64 and a 200 day simple moving average of $66.10. Bruker has a 1-year low of $54.55 and a 1-year high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.75 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. Bruker’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.74 earnings per share. On average, analysts predict that Bruker will post 2.39 earnings per share for the current year.

Hedge Funds Weigh In On Bruker

Several institutional investors and hedge funds have recently made changes to their positions in BRKR. First Horizon Advisors Inc. increased its stake in Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after purchasing an additional 218 shares during the period. Covestor Ltd boosted its position in Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after buying an additional 210 shares during the period. UMB Bank n.a. grew its holdings in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after acquiring an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Bruker in the second quarter valued at about $52,000. Finally, GAMMA Investing LLC raised its stake in shares of Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after acquiring an additional 388 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.